Concord Medical Services Holdings Ltd: Form 20-F for the period ended Dec 31, 2016
Filed with the SEC on May 1, 2017 and accepted by EDGAR at May 1, 2017, 16:07 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2016-01-01 to 2016-12-31 | $65.5m | us-gaap:Revenues |
| Cost of revenue | 12 months2016-01-01 to 2016-12-31 | $41.3m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2016-01-01 to 2016-12-31 | $24.3m | us-gaap:GrossProfit |
| Operating income | 12 months2016-01-01 to 2016-12-31 | −$24.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2016-01-01 to 2016-12-31 | $12.9m | us-gaap:InterestExpense |
| Income tax | 12 months2016-01-01 to 2016-12-31 | $8.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2016-01-01 to 2016-12-31 | −$37.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | −$0.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2016-01-01 to 2016-12-31 | −$0.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2016-01-01 to 2016-12-31 | 130,631,867 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | −$11.2m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $11.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2016-01-01 to 2016-12-31 | $41.2m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months2016-01-01 to 2016-12-31 | $4.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-12-31 | $27.4m | us-gaap:Cash |
| Current assets | At period end2016-12-31 | $172.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $465.0m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $137.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $287.6m | us-gaap:Liabilities |
| Long-term debt | At period end2016-12-31 | $31.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-12-31 | $11.9m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2016-12-31 | $81.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2016-12-31 | $168.0m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2016-12-31 | 130,091,977 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001144204-17-023641. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.